

FURANTOINA[®] comprimidos
Nitrofurantoin. Urinary chemotherapy treatment

FURANTOINA, with the principal ingredient of nitrofurantoin is a chemotherapy treatment, specifically for chronic or acute bacterial infections in the urinary tract. It is effective against germs which are habitually resistant to antibiotics and sulfamides, like the generics Proteus and Pseudomonas and does not provoke the apparition of resistant strains.

Composition

Each tablet contains:

Principal ingredient:

Nitrofurantoin (DCI).....50mg

Excipients:

Povidone, carboxymethyl starch (Type A), dehydrated calcium hydrogen phosphate, talc and magnesium stearate.

Indications

All bacterial infections of the urinary-bladder tract caused by germs sensitive to nitrofurantoin: pyelitis, pyelonephritis, cystitis, prostatitis, urethritis.

Chemo-prophylaxis in urinary explorations or interventions.

Dosage

Adults: 1-2 tablets, 3 times a day.

Children: Up to 2 years old: Half a tablet 3 or 4 times a day.

Between 2 and 8 years old: One tablet 3-4 times a day.

Dosage regime

You are recommended to take FURANTOINA during meals or with a glass of cold milk and never on an empty stomach.

Given FURANTOINA's superior absorption in relation to macro-crystalline products or those with delayed break-up, it is hardly ever necessary to surpass the doses indicated above.

Counter indications

Serious hepatic or renal insufficiency.

Incompatibilities

Acidifiers of the urinary pH increase the digestive absorption of nitrofurantoin, whereas alkalizing agents and nalidixic acid decrease it.

Secondary effects

Can provoke nausea and vomiting, which can be avoided by taking this medicine with meals. Occasionally allergic reactions and polyneuritis disorders (these during extended treatments) have been reported, these give way when medication is stopped.

Intoxication and its treatment

Acute intoxication with this medical speciality is due to its elevated therapeutic index. In case of accidental intoxication, which can only be produced by ingesting large doses, the general norms for the rapid elimination of medicines will be followed, (stomach wash and increase in urinary output).

Presentation

Tablets: Containers of 50 and 25.
Tablets: Clinical container of 500.

Alternative presentation

Suspension: 80ml jar

Note: Please communicate any irregularity observed to us, indicating the number of the 'lote' which is indicated on the exterior wrapping.

Maintain medicines out of sight and reach of children.

With medical prescription.

Holder of the authorisation for the commercialisation and fabrication of the product.

LABORATORIOS ERN, S.A. Pedro IV, 499 - 08020 Barcelona, España
Tel: 93 314 80 11 Fax: 93 314 40 96

Responsible for fabrication.

Laboratorios ERN, S.A. Gorcs i LLadó, 188 – 08210 Barberá del Vallés, Barcelona.
España.
Laboratorios ERN, S.A. Perú, 228 – 08020 Barcelona. España.